DDP 200
Latest Information Update: 29 Dec 2009
At a glance
- Originator Dynogen Pharmaceuticals
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Overactive bladder
Most Recent Events
- 18 Oct 2005 Phase-II clinical trials in Overactive bladder in USA (unspecified route)
- 20 Mar 2004 Phase-I clinical trials in Overactive bladder in USA (unspecified route)
- 20 Jan 2004 Preclinical trials in Overactive bladder in USA (unspecified route)